Loading stock data…
ONCO
$1.08+0.13 (+14.06%)
Market OpenUpdated 3:07 PM EDT
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Onconetix, Inc. in the Healthcare sector is trading at $1.08 with a market capitalization of $1M. The stock is currently near its 52-week low of $0.91, remaining 98.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $21,457↓ | $303,596 | $303,651↑ | $106,494↑ | $101,630 |
| Gross Profit | -$1,655↓ | $247,684↓ | $268,894↑ | $70,503↑ | $45,832 |
| Operating Income | -$2.09M↓ | -$1.28M↑ | -$2.07M↓ | -$1.34M↑ | -$1.65M |
| Net Income | -$4.21M↓ | $5.67M↑ | -$8.78M↓ | -$2.37M↑ | -$8.55M |
Peer Comparison
JNJUNHPFE
Fundamentals
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vit...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.25M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
0.00
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-82.58%
Volume
Today's trading volume
244,361
Recent News
BC-Most Active Stocks
Megan Holdings Ltd. 7,893,938 0.2401
Realbotix Announces the Sale of Realbotix, LLC Subsidiary to Onconetix
Realbotix (XBOT.V) on Thursday said it entered into a definitive agreement with Onconetix, Inc (NASD
Onconetix announces financing through private placement, debt settlement
Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shares of the Company’s common stock, $0.00001 par value per share, for an aggregate purchase price of approximately $12.9 million. Approximately $9.3 million was paid in cash and the balance was used to offset certain amounts owed by the Company to certain investo